Jennifer Pierce
Family · Tishomingo, MSNPI 1396727590
Payments from drug & device makers
Across 199 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$423
- Novo Nordisk$194
- Pfizer$166
- Boehringer Ingelheim$160
- Lilly USA, LLC$131
- plus $786 from 20 others
What the payments were for
- Food & beverage$2,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 90 | $1,087 |
| Amgen(2 entities) | 24 | $423 |
| Novo Nordisk | 13 | $194 |
| Pfizer | 9 | $166 |
| Boehringer Ingelheim | 9 | $160 |
| Lilly USA, LLC | 8 | $131 |
| Bayer | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| GSK | 5 | $77 |
| Johnson & Johnson | 4 | $75 |
| Abbott | 3 | $70 |
| Xeris Pharmaceuticals, Inc. | 2 | $50 |
| Novartis | 3 | $48 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $44 |
| Amarin Pharma, Inc. | 2 | $42 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Medtronic | 1 | $19 |
| Theratechnologies Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Scynexis, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Gilead | 1 | $11 |
| Genentech USA, Inc. | 1 | $2 |
How this compares
$2,947 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 699 | $1,217,609 |
| EliquisApixaban | 375 | $618,215 |
| JardianceEmpagliflozin | 271 | $424,276 |
| FarxigaDapagliflozin Propanediol | 201 | $309,959 |
| XareltoRivaroxaban | 242 | $268,572 |
| MounjaroTirzepatide | 192 | $260,933 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $208,025 |
| Tresiba Flextouch U-100Insulin Degludec | 133 | $177,269 |
| EntrestoSacubitril/Valsartan | 119 | $143,027 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $121,412 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $90,054 |
| LinzessLinaclotide | 77 | $81,174 |
| JanuviaSitagliptin Phosphate | 42 | $64,067 |
| TradjentaLinagliptin | 49 | $62,925 |
| VascepaIcosapent Ethyl | 63 | $46,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $194 | $1,250,286724 claims |
| PfizerEliquis | $166 | $618,215375 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $160 | $577,255378 claims |
| AstraZenecaFarxiga, Brilinta | $15 | $327,587217 claims |
| Lilly USA, LLCMounjaro, Trulicity | $131 | $297,753216 claims |
| Johnson & JohnsonXarelto | $75 | $268,572242 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $77 | $230,151140 claims |
| NovartisEntresto | $48 | $143,027119 claims |
| MerckJanuvia, Janumet Xr, Janumet | $14 | $115,67084 claims |
| AbbVieLinzess | $1,087 | $81,17477 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $29,51826 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $15 | $4,98511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Tishomingo
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.